R&D channel feed

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

Last month

In­tel­lia re­ports case of liv­er tox­i­c­i­ty in AT­TR gene edit­ing study

Last month

Mer­ck, Dai­ichi Sankyo scrap FDA ap­pli­ca­tion for HER3 ADC af­ter sur­vival miss

Last month
Pharma

Oric locks down cash for Phase 3 prostate can­cer tri­al with ear­ly da­ta in hand

Last month

Pep­Gen ditch­es Duchenne pro­grams af­ter mid-stage fail, switch­es to pre­vi­ous­ly halt­ed mus­cle wast­ing ther­a­py

Last month

The fate of Mod­er­na’s next-gen Covid shot looms large af­ter a flur­ry of pol­i­cy changes

Last month
FDA+

GSK, Spero re­port Phase 3 win for UTI an­tibi­ot­ic; Sper­o's stock soars

Last month

Strand Ther­a­peu­tics re­ports promis­ing start for mR­NA can­cer ther­a­py

Last month

In­flaRx cans Go­hibic de­vel­op­ment af­ter skin dis­ease tri­al stopped for fu­til­i­ty

Last month

Bound­less Bio changes plans for can­cer drug af­ter tox­i­c­i­ty is­sues

Last month
People

Gil­gamesh’s short-act­ing psy­che­del­ic drug shows rapid ef­fect in Phase 2 de­pres­sion study

Last month

Prothena’s amy­loi­do­sis drug flops again, spend­ing and staff cuts are on the way

Last month
People

Ku­ra spells out piv­otal AML tri­al win as it gears up to com­pete with Syn­dax

Last month

Gilead notch­es an­oth­er Phase 3 win for Trodelvy in triple-neg­a­tive breast can­cer

Last month
Pharma

Volas­tra un­veils first hu­man da­ta of its sol­id tu­mor drug tar­get

Last month

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

Last month

Roche con­firms over­all sur­vival ben­e­fit for PI3K in­hibitor in breast can­cer

Last month
Pharma

Jazz out­lines full sur­vival da­ta for lung can­cer drug Zepzel­ca

Last month
Pharma

BioN­Tech in­vests £1B in grow­ing UK foot­print un­der ex­pand­ed pact with gov­ern­ment

Last month
Deals

Co­caine vac­cine, a long­shot at­tempt to quell crav­ings, yields mixed da­ta in small study

Last month

Genen­tech ex­pands deal with mol­e­c­u­lar glue biotech Ori­o­n­is for $105M up­front

Last month
Deals

How PureTech’s lung fi­bro­sis drug stacks up against the com­pe­ti­tion

Last month

In his first ma­jor pol­i­cy roll­out, Vinay Prasad looks to chal­lenge ex­ist­ing 'dog­ma' on Covid vac­cines

Last month
FDA+

CRISPR Ther­a­peu­tics part­ners with siR­NA com­pa­ny, show­ing that gene edit­ing isn’t the on­ly an­swer

Last month
Cell/Gene Tx
First page Previous page 3456789 Next page Last page
A service from the Financial Times